Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 219-223

  Lorente, Leonardo ^a   Lorenzo, Lisset ^a   Martín, María M ^a   Jiménez, Alejandro ^a   Mora, María L ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Gram negative bacilli; Infusion; Meropenem; Pneumonia

Indexed keywords

BETA LACTAM ANTIBIOTIC; MEROPENEM; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; APACHE; ARTICLE; BACTERICIDAL ACTIVITY; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG INTERMITTENT THERAPY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SERRATIA MARCESCENS; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 33144478109     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G467     Document Type: Article

References (35)

1. Leu HS, Kaiser DL, Mori M, Woolson RF, Wenzel RP. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol 1989;129:1258-67.
2. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients; a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
3. Heyland DK, Cook DJ, Griffith LE, Keenan SP, Brun-Buisson C. For the Canadian Critical Care Trials Group. The attributable morbidity and mortality of ventilator associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 1999;159:1249-56.
4. Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003;47:365-72.
5. Drusano GL Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988;32:289-97.
6. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-83.
7. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
8. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001;7:589-96.
9. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999;115(suppl 3):19S-23S.
10. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005;49:1337-9.
11. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003;23:988-91.
12. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003;52:518-21.
13. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116-23.
14. Krueger WA, Bulitta J, Kinzing-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005;49:1881-9.
15. Keil S, Wiedemann B. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother 1997;41:1215-9.
16. Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999;43:523-37.
17. Elkhaili H, Peter JD, Pompei D, et al. Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection. Clin Microbiol Infect 1998;4:18-26.
18. Domenig C, Traunmuller F, Kozek S, et al. Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection. Transplantation 2001;71:744-5.
19. Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 2004;24:803-7.
20. Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004;24:1641-5.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Takeuchi Y, Takebayashi Y, Sunagawa M, et al. The stability of a novel carbapenem antibiotic, meropenem (SM-7338), in a solid state formulation for injection. Chem Pharm Bull 1993;41:1998-2002.
23. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal betalactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002;46:2327-32.
24. Patel PR, Cook SE. Stability of meropenem in intravenous solution. Am J Health Syst Pharm 1997;54:412-21.
25. Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 2003;34:627-9.
26. Package insert. Meronem (meropenem). Caponago, Italy: AstraZeneca, April 1, 2002.
27. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients, Antimicrob Agents Chemother 1995;39:650-5.
28. Vincent JL, Moreno R, Takala J, et al. the Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. On befalf of the Working Group on Sepsis-related Problems of lthe European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
29. Brun-Buisson C, Solet JP, Schweich H, Briere S, Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin vs ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998;26:364-54.
30. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108:1655-62.
31. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hopsitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994;38:547-57.
32. Masterton R, Drusano G, Paterson DL, Park G. Approriate antimicrobial treatment in nosocomial infections-the clinical challenges. Hosp Infect 2003;55(suppl 1):1-12.
33. Mattoes HM, Kuti JL, drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004;26:1187-98.
34. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections Clin Infect Dis 2005;40(suppl 2):S99-104.
35. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005;49:461-3.